We found that TCF3 was expressed at significantly higher levels in most cancers, especially in glioblastoma multiforme (GBM), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), pancreatic adenocarcinoma (PAAD), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (LAML), and cholangiocarcinoma (CHOL). This evidence concerns the gene TCF3 and invasive breast carcinoma.